Autoimmun vermittelte Enzephalitis

Autoimmunenzephalitiden bilden eine heterogene Gruppe neurologischer und psychiatrischer Erkrankungen. Es werden Antikörper-vermittelte Enzephalitiden von den häufig paraneoplastisch auftretenden Antikörper-assoziierten Enzephalitiden unterschieden. Während die Antikörper im ersten Fall direkt krankheitsverursachend sind, dienen sie im zweiten Fall als diagnostischer Biomarker mit hoher Aussagekraft für einen zugrunde liegenden Tumor.

• Literatur

• 1 Prüss H. Autoantibodies in neurological disease. Nat Rev Immunol 2021; 21: 798-813
• 2 Graus F, Titulaer MJ, Balu R. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391-404
• 3 Dalmau J, Armangué T, Planaguma J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 2019; 18: 1045-1057
• 4 Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med 2018; 378: 840-851
• 5 Prüss H, Finke C, Holtje M. et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911
• 6 Armangué T, Spatola M, Vlagea A. et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol 2018; 17: 760-772
• 7 Graus F, Vogrig A, Muniz-Castrillo S. et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8: e1014
• 8 Graus F, Delattre JY, Antoine JC. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-1140
• 9 Saiz A, Blanco Y, Sabater L. et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563
• 10 Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Reviews Clin Oncol 2019; 16: 535-548
• 11 Herken J, Prüss H. Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients. Front Psychiatry 2017; 8: 25
• 12 Rößling R, Prüss H. Apheresis in Autoimmune Encephalitis and Autoimmune Dementia. J Clin Med 2020; 9: 2683
• 13 Gelpi E, Hoftberger R, Graus F. et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016; 132: 531-543
• 14 Werner J, Jelcic I, Schwarz EI. et al. Anti-IgLON5 Disease: A New Bulbar-Onset Motor Neuron Mimic Syndrome. Neurol Neuroimmunol Neuroinflamm 2021; 8: e962
• 15 Blinder T, Lewerenz J. Cerebrospinal Fluid Findings in Patients With Autoimmune Encephalitis-A Systematic Analysis. Front Neurol 2019; 10: 804
• 16 Schmitt SE, Pargeon K, Frechette ES. et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79: 1094-1100
• 17 Gultekin SH, Rosenfeld MR, Voltz R. et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000; 123: 1481-1494
• 18 Scheibe F, Prüss H, Mengel AM. et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88: 366-370
• 19 Wickel J, Chung HY, Platzer S. et al. Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis. Trials 2020; 21: 625
• 20 van Sonderen A, Thijs RD, Coenders EC. et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87: 1449-1456
• 21 Finke C, Prüss H, Heine J. et al. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurol 2017; 74: 50-59